Serum Calcification Propensity and CPP2 Size - Deranged Mineral Buffering and The Risk of Mortality in Older Adults
aging and disease · 2026
DOI: 10.14336/ad.2025.1335 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift aging and disease, 2026. Verfasst von Mirjam Schuchardt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Nephrology and Med….
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Ageing is associated with increased vascular calcification. However, the parallels with chronic kidney disease are unclear, where secondary calciprotein particles (CPP2) are increasingly formed due to insufficient mineral buffering. CPP2 induce vascular dysfunction as well as calcification and thereby could increase mortality risk. This study aimed to assess whether indicators of deranged mineral buffering are associated with mortality in older adults. Serum calcification propensity (T50) and hydrodynamic radius of CPP2 were assessed in 1,566 participants of the population-based Berlin Initiative (cohort) Study (BIS) of older adults with a mean age of 81.8 years. The associations with all-cause and cardiovascular mortality were assessed using multivariable Cox regression models, adjusted for cardiovascular risk factors. During a median follow-up of 9.1 years, 814 participants died, of whom 350 died from a cardiovascular cause. An increase of CPP2 size was associated with increased Hazard Ratios (HR) for all-cause mortality (age and sex adjusted HR [95% CI], 1.19 [1.10-1.28]; fully adjusted for other confounders HR [95% CI], 1.15 [1.06-1.24]) and cardiovascular mortality when age and sex adjusted (HR [95% CI], 1.17 [1.05-1.31]) but not when fully adjusted (HR [95% CI], 1.11 [0.98-1.25]). Furthermore, each 60 min decrease of T50 was associated with increased HR for all-cause mortality when age and sex adjusted (HR [95% CI], 1.10 [1.03-1.17]) but not when fully adjusted (HR [95% CI], 1.06 [1.00-1.14]), and without clear association with cardiovascular mortality (fully adjusted, HR [95% CI], 0.98 [0.89-1.08]). Disturbed mineral buffering, as inferred from increased CPP2 size, may be a novel and independent risk factor for mortality in older adults.
Autor:innen und Institutionen
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Nephrology and Medical Intensive Care, 12203 Berlin, Germany.
- Faculty of Medicine, Medical School Berlin, 14513 Berlin, Germany.
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Institute of Public Health, 10117 Berlin, Germany.
- Institute for Physiology and Pathophysiology, Johannes Kepler University Linz, 4040 Linz, Austria.
- Calciscon AG, 2503 Biel, Switzerland.
- DZHK (German Centre for Cardiovascular Research), 10785 Berlin, Germany.
Zitieren
APA
Schuchardt, M., Mielke, N., Barghouth, M. H., Herrmann, J., Alesutan, I., Pasch, A., van der Giet, M., Eckardt, K. U., Schaeffner, E., Ebert, N., Tölle, M., & Voelkl, J. (2026). Serum Calcification Propensity and CPP2 Size - Deranged Mineral Buffering and The Risk of Mortality in Older Adults. aging and disease. https://doi.org/10.14336/ad.2025.1335
Vancouver
Schuchardt M, Mielke N, Barghouth MH, Herrmann J, Alesutan I, Pasch A, et al. Serum Calcification Propensity and CPP2 Size - Deranged Mineral Buffering and The Risk of Mortality in Older Adults. aging and disease. 2026. doi:10.14336/ad.2025.1335
BibTeX
@article{Schuchardt2026,
author = {Schuchardt, Mirjam and Mielke, Nina and Barghouth, Muhammad Helmi and Herrmann, Jaqueline and Alesutan, Ioana and Pasch, Andreas and van der Giet, Markus and Eckardt, Kai-Uwe and Schaeffner, Elke and Ebert, Natalie and Tölle, Markus and Voelkl, Jakob},
title = {Serum Calcification Propensity and CPP2 Size - Deranged Mineral Buffering and The Risk of Mortality in Older Adults},
journal = {aging and disease},
year = {2026},
doi = {10.14336/ad.2025.1335}
}
EUVIMED